-
'Avatar: Fire and Ash' at number one in N.America for fifth straight week
-
Limited internet returns in Iran after protest blackout
-
Syria's leader agrees truce deal with Kurds after govt troops advance
-
Smith's penalty sees Quins eliminate La Rochelle, Bordeaux secure top seeding
-
Atletico edge Alaves to strengthen Liga top-four hold
-
Uganda president says opposition 'terrorists' in victory speech
-
New Zealand register first ODI series win in India despite Kohli ton
-
Elvira wins Dubai Invitational after Lowry's last hole meltdown
-
Jeong snatches Union late draw at Stuttgart in Bundesliga
-
Man Utd's Martinez hits back at Scholes after height jibes
-
Frank on the brink as Romero calls for unity amid Spurs 'disaster'
-
Chile declares emergency as wildfires kill at least 15
-
Europe hits back at Trump tariff threat over Greenland
-
Men's Fashion Week in Paris: what to watch
-
McGrath goes top of slalom standings with Wengen win
-
No Venus fairytale as Alcaraz, Sabalenka win Melbourne openers
-
Iran considers 'gradually' restoring internet after shutdown
-
Mitchell, Phillips tons guide New Zealand to 337-8 in ODI decider
-
Flailing Frankfurt sack coach Toppmoeller
-
Kurdish forces withdraw from Syria's largest oil field as govt forces advance
-
'Proud' Venus Williams, 45, exits Australian Open after epic battle
-
Vonn in Olympic form with another World Cup podium in Tarvisio super-G
-
Alcaraz kicks off career Grand Slam bid with tough Australian Open test
-
Hosts Morocco face Mane's Senegal for AFCON glory
-
Europe scrambles to respond to Trump tariff threat
-
Venus Williams, 45, exits Australian Open after epic battle
-
Taiwan's Lin wins India Open marred by 'dirty' conditions
-
Indonesia rescuers find body from plane crash
-
Kurdish-led forces withdraw from Syria's largest oil field: monitor
-
Ball girl collapses in Australian Open heat as players rush to help
-
France's Moutet booed for underarm match point serve in Melbourne
-
Zverev happy with response after wobble in opening Melbourne win
-
'Bring it on': UK's Labour readies for EU reset fight
-
New Zealand's Wollaston wins again to lead Tour Down Under
-
Zverev wobbles but wins at Australian Open as Alcaraz enters fray
-
British qualifier upsets 20th seed Cobolli to make mum proud
-
Zverev drops set on way to Australian Open second round
-
Indonesian rescuers find debris from missing plane
-
Wembanyama scores 39 as Spurs overcome Edwards, Wolves in thriller
-
Heartbreak for Allen as Broncos beat Bills in playoff thriller
-
British qualifier upsets 20th seed Cobolli in Melbourne
-
Paolini races into round two to kickstart Australian Open
-
Portugal presidential vote wide open as far-right surge expected
-
Lutz kicks Broncos to overtime thriller as Bills, Allen fall short
-
Marchand closes Austin Pro Swim with 200m breaststroke win
-
Raducanu says Australian Open schedule 'does not make sense'
-
Australia great Martyn says he was given '50/50 chance' of survival
-
Top-ranked Alcaraz, Sabalenka headline Australian Open day one
-
Haiti security forces commence major anti-gang operation
-
NFL's Giants ink John Harbaugh as new head coach
Ozempic slimming craze sweeps Kosovo despite side effects
Kosovo influencer Tringa Kadriu sees the slimming drug Ozempic as a chance to shed excess pounds -- and she is not the only one in her Balkan nation, where more than half the population is overweight.
"I want to lose 15-16 kilos (33-35 pounds) in two months," Kadriu, 29, told AFP, "and then I'll continue with fitness".
Ozempic, approved in the United States to treat diabetes in 2017, has found an international market for people trying to lose weight.
Despite its cost, the drug has soared in popularity in Kosovo, a country of 1.7 million.
While Kosovo authorities have not sanctioned the drug's use for weight loss, they have noted their limited means to confront use of a drug widely available in the country.
Merita Emini-Sadiku, who heads the Kosovo university hospital's endocrinology clinic, said the cost of the drug had soared.
"The monthly dose used to be 75-80 euros ($85-91), while now it is 130-140 euros ($147-159), probably due to high demand," she said.
But she warned that "Ozempic has side effects that people are not aware of".
Ozempic use can potentially cause issues including thyroid cancer, pancreatitis, gastroparesis and bowel obstruction, according to the latest studies.
- 'Constant demand' -
Meant to treat Type 2 diabetes -- of which the WHO says Kosovo has lower than average levels -- the drug regulates blood sugar levels but also helps suppress hunger, leading to a lower calorie intake.
As a result, its potentially cancerous complications have done little to stem the drug's popularity or availability.
"I checked a lot of pharmacies in Kosovo and I noticed that Ozempic is very easy to get," said Kadriu, adding that pharmacists even suggested she gradually increase her dosage.
A worker at a pharmacy in the capital Pristina's downtown, who asked to remain anonymous, said she had trouble recalling when someone last came into her pharmacy to buy Ozempic with a diabetes prescription.
"But we have a constant demand for Ozempic without a prescription. You can guess why," she said.
Given its availability, Emini-Sadiku said authorities should exercise greater control over Ozempic's distribution.
But Bujar Vitija, a journalist specialising in health, said that would be tricky to achieve given Kosovo's poor health record-keeping.
"Unfortunately there is no data," Vitija said.
With 1,500 to 1,600 private pharmacies in Kosovo, the country's 20 pharmaceutical inspectors have their work cut out for them, he added.
- Ozempic 'every day' -
While Kosovo has lower levels of obesity than the European average, more than 57 percent of the population is overweight and 20 percent is clinically obese, according to a 2019 World Health Organization report.
And women, who are more likely to face societal pressure to be thin, were 66 percent more likely to be obese than men, the WHO report found.
But not every Kosovar who has used Ozempic had the best experience with the drug.
"I took Ozempic on the advice of a doctor for two years but it had no effect," said 48-year-old merchant Lulzim Rrahmani, adding that three of his relatives even experienced "a negative effect of the drug".
"It was just a waste of money and time."
Given the risk of side effects, Emini-Sadiku said Ozempic was "by no means to be taken without a doctor's prescription".
Yet Kadriu said she would not be deterred, adding that she saw colleagues taking the drug "every day at work".
"I don't see any symptom that would deter me."
N.Schaad--VB